TECFIDERA

TECFIDERA. It is an oral medication primarily used for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug is classified as a disease-modifying therapy designed to reduce the frequency of clinical exacerbations and delay the accumulation of physical disability. Its development and approval marked a significant shift towards oral therapeutic options for a condition historically managed with injectable or infused agents.

Medical uses

It is indicated by the U.S. Food and Drug Administration and the European Medicines Agency for adult patients with relapsing forms of multiple sclerosis. Clinical trials, such as the pivotal DEFINE and CONFIRM studies, demonstrated its efficacy in reducing annualized relapse rates and slowing the progression of disability as measured by the Expanded Disability Status Scale. It is not indicated for the treatment of primary progressive multiple sclerosis. Treatment decisions are typically made by a neurologist specializing in neuroimmunology or demyelinating diseases.

Adverse effects

The most common adverse reactions include flushing and gastrointestinal events, such as abdominal pain, diarrhea, and nausea. These effects are often transient and most prevalent during the initial month of therapy. A serious but rare adverse effect is a decline in lymphocyte counts, necessitating regular monitoring of complete blood count parameters as recommended in the prescribing information from the U.S. Food and Drug Administration. Cases of progressive multifocal leukoencephalopathy have been reported in patients treated with this drug, leading to boxed warnings from regulatory agencies.

Pharmacology

The active metabolite is monomethyl fumarate, which is believed to exert its therapeutic effects through activation of the nuclear factor erythroid 2-related factor 2 pathway, a mechanism involved in the cellular response to oxidative stress. This pathway modulates the expression of antioxidant genes and exerts anti-inflammatory effects within the central nervous system. Pharmacokinetic studies show it is rapidly converted by esterases in the gastrointestinal tract, blood, and tissues, with the metabolite reaching peak plasma concentrations within a few hours.

History

The development program was led by Biogen, building upon earlier research into fumaric acid esters used for the treatment of psoriasis in Europe. The key Phase III clinical trials, DEFINE and CONFIRM, were conducted in the late 2000s and published in *The New England Journal of Medicine*. Based on this data, it received its initial approval from the U.S. Food and Drug Administration in 2013 and subsequently from the European Medicines Agency. Its introduction significantly altered the multiple sclerosis treatment landscape, becoming one of the most prescribed oral disease-modifying therapies globally.

Society and culture

Its high cost has been a subject of discussion within healthcare systems, including debates over formulary placement by entities like the National Health Service in the United Kingdom. The drug has been featured in medical education programs by organizations such as the American Academy of Neurology. Patient assistance programs have been established by the manufacturer to support access. The therapy's success contributed substantially to the financial performance of Biogen during the 2010s, influencing research and development investments in other neurological areas like Alzheimer's disease and spinal muscular atrophy. Category:Drugs